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Inﬂammatory responseBrown spider dermonecrotic toxins (phospholipases-D) are the most well-characterized biochemical
constituents of Loxosceles spp. venom. Recombinant forms are capable of reproducing most cutaneous and
systemic manifestations such as dermonecrotic lesions, hematological disorders, and renal failure. There is
currently no direct conﬁrmation for a relationship between dermonecrosis and inﬂammation induced by
dermonecrotic toxins and their enzymatic activity. We modiﬁed a toxin isoform by site-directed mutagenesis
to determine if phospholipase-D activity is directly related to these biological effects. The mutated toxin
contains an alanine substitution for a histidine residue at position 12 (in the conserved catalytic domain of
Loxosceles intermedia Recombinant Dermonecrotic Toxin — LiRecDT1). LiRecDT1H12A sphingomyelinase
activity was drastically reduced, despite the fact that circular dichroism analysis demonstrated similar spectra
for both toxin isoforms, conﬁrming that the mutation did not change general secondary structures of the
molecule or its stability. Antisera against whole venom and LiRecDT1 showed cross-reactivity to both
recombinant toxins by ELISA and immunoblotting. Dermonecrosis was abolished by the mutation, and rabbit
skin revealed a decreased inﬂammatory response to LiRecDT1H12A compared to LiRecDT1. Residual
phospholipase activity was observed with increasing concentrations of LiRecDT1H12A by dermonecrosis and
ﬂuorometric measurement in vitro. Lipid arrays showed that the mutated toxin has an afﬁnity for the same
lipids LiRecDT1, and both toxins were detected on RAEC cell surfaces. Data from in vitro choline release and
HPTLC analyses of LiRecDT1-treated puriﬁed phospholipids and RAEC membrane detergent-extracts
corroborate with the morphological changes. These data suggest a phospholipase-D dependent mechanism
of toxicity, which has no substrate speciﬁcity and thus utilizes a broad range of bioactive lipids., Federal University of Paraná,
l. Fax: +55 41 3266 2042.
sevier OA license.© 2010 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Dermonecrotic toxins are biologically and biochemically well-
characterized constituents of the Brown spider (genus Loxosceles)
venom complex mixture. Most of the described toxic effects asso-
ciated with brown spiders, such as an intense inﬂammatory response
at the bite site, hemostasis disorders, renal injury, platelet aggrega-
tion, and the typical necrotic lesion of the skin, can be experimentally
reproduced using dermonecrotic toxins [1–5].
Histological ﬁndings for animals exposed to whole venom have
shown subendothelial blebs, vacuoles, endothelial cell membrane
degeneration of the blood vessel walls, and ﬁbrin and thrombusformation [6,7]. Moreover, Paludo et al. [8] demonstrated morpho-
logical alterations in an endothelial cell line derived from the rabbit
aorta (RAEC) treated with whole venom such as cell retraction,
homophilic disadhesion, and an increase in ﬁlopodia projections. In
addition, venom was observed to bind to the cell surface and
extracellular matrix. These direct cytotoxic effects on blood vessel
cells could be responsible for triggering intense inﬁltration of
inﬂammatory cells. In addition, they could indirectly lead to leukocyte
and platelet activation, disseminated intravascular coagulation, and
an increase in vessel permeability.
Dermonecrotic toxins are very characteristic and conserved mol-
ecules among Loxosceles species. Currently, more than ten complete
mRNA sequences for Loxosceles spp. dermonecrotic toxins have been
deposited in the nucleotide databases [3,9]. These toxins were
biochemically reported as sphingomyelinase-D (or sphingomyelin
phosphodiesterase D; E.C. 3.1.4.41) family members due to their
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and Lynch [10] suggested that the dermonecrotic toxin family should
be more accurately named phospholipases-D due to their additional
hydrolytic activity upon glycerophospholipids.
Six isoforms of phospholipase-D were cloned from a cDNA library
of L. intermedia gland venom and then expressed; they were shown to
have similar toxic effects to those of native venom toxins [11–15].
Appel et al. [11] performed an alignment analysis of the cDNA-
deduced amino acid sequences for LiRecDT1 (ABA62021), LiRecDT2
(ABB69098), LiRecDT3 (ABB71184), LiRecDT4 (ABD91846), LiRecDT5
(ABD91847), and LiRecDT6 (ABO87656). The results of this alignment
corroborated the crystal structure analysis of a dermonecrotic toxin
described byMurakami et al. [16] that suggested conserved residues at
the proposed catalytic site.
Two histidine residues (H12 and H47) are postulated to be
responsible for an acid–base reaction stabilized by Mg+2 ion coordina-
tion at the catalytic site. In the intermediate steps of the hypothetical
mechanism, theHis12 residuemust be deprotonated for the subsequent
nucleophilic attack of a water molecule to succeed. This mechanism can
be followedby theﬁnal release of ceramide 1-phosphate (C1P) from the
sphingomyelin substrate or lysophosphatidic acid (LPA) from a lyso-
phospholipid [16,17].
Studies on lipidmetabolismhave shown that glycerophospholipids
and sphingolipids are not simply structural constituents of cell
membranes. Bioactive lipid mediators have been shown to play a
major role in complex signaling pathways that control several cellular
dynamics such as cell growth, survival, differentiation, and motility.
They have also been shown to play roles in various pathophysiologic
processes, all of which involve several G-protein-coupled receptors
(GPCRs) and kinase cascades [18–20].
Pettus et al. [21] showed that C1P, rather than ceramide, functions
as the proximal mediator of arachidonic acid release. Exogenous C1P
alone can stimulate arachidonic acid release and prostaglandin E2
formation. Treatment of cells with spider venom sphingomyelinase-D
to produce C1P from membrane sphingomyelin can elicit the ara-
chidonic acid response [22]. Likewise, phospholipase-D can induce
LPA formation by catalyzing the hydrolysis of a lyso-phospholipid
precursor. In quiescent ﬁbroblasts, exogenous PLD (from Streptomyces
chromofuscus) generated bioactive LPA from pre-existing lysophos-
phatidylcholine in the outer membrane leaﬂet, resulting in the ac-
tivation of G-protein-coupled LPA receptors and subsequent
activation of the Ras, Rho, and Ca2+ signaling pathways [23]. Similarly,
recombinant SMaseD from L. laeta was able to hydrolyze lysophos-
phatidylcholine to produce LPA and choline. Recombinant PLD from
L. recluse also degraded several puriﬁed lysophospholipids and
sphingomyelin substrates [10,24]. Gene expression proﬁles of
human ﬁbroblasts treated with L. recluse isoform I recombinant
toxin (SMD) showed the upregulation of genes related to human
cytokines and genes involved in the glycosphingolipid metabolism
pathway. Furthermore, they speculated that sphingomyelinase
activity on cell membranes, which results in ceramide 1-phosphate
(C1P) production, induces the pro-inﬂammatory molecules NF-kB
and IL-8 [25].
In the literature, there are several proteins with enzymatic activities
(as well as catalytic domain structures) that are not responsible for the
toxicity observed in experimental systems. Snake venom phospholi-
pases A2 (PLA2) present remarkable diversity in their biological effects
in addition to their catalytic activity. Sequence alignment analyses of
functionally related PLA2 are frequently used to predict the structural
determinants of these effects, and the predictions are subsequently
evaluated by site-directed mutagenesis experiments and functional
assays [26]. In thisway, Sakamoto et al. [27] demonstrated thatmodiﬁed
CyaAs (calmodulin-dependent adenylate cyclases from Bordetella
pertussis) display hemolytic activity identical to the original toxin.
The absence of a clear correlation between catalysis and phar-
macological activity and the diversity of biological effects raisesquestions regarding the structural basis of these biological functions.
Nephrotoxicity and hemolysis directly induced by phospholipase-D
activity were already reported in literature [10,28,29]. However,
dermonecrosis in vivo and inﬂammatory response triggered by brown
spider phospholipase-D toxin were not yet described as directly
dependent on its catalytic activity. In this report, we used a site-
directed mutagenesis strategy to clone and express a mutated form of
the previously reported dermonecrotic toxin known as LiRecDT1
(ABA62021) [12]. The substitution of a histidine residue at position 12
in the amino acid sequence with an alanine was performed to modify
the organization of the active site and interfere with the catalytic
reaction of the enzyme.
We investigate the correlation between the toxicity reported in
loxoscelism (mainly characterized by dermonecrosis and inﬂamma-
tory disturbance) and the biochemical and catalytic mechanism of
phospholipase-D. We report evidence demonstrating the dependence
of the biological effects on phospholipase-D activity of dermonecrotic
toxin in vivo and in vitro, bringing new insights to the molecular
mechanism of phospholipase-D activity.
2. Materials and methods
2.1. Reagents
Whole venom from L. intermedia obtained by electrostimulation
(15 V) of the cephalothorax of spiders captured in the wild was solu-
bilized in PBS andmaintained frozen until used, as described by Feitosa
et al. [30]. Polyclonal antibodies to L. intermediaphospholipase-D toxin
and whole venom were produced in rabbits as described by Chaim
et al. [12]. Hyperimmune IgGs were puriﬁed from sera using amixture
of Protein-A and Protein-G Sepharose beads (GE Healthcare, Chalfont
St Giles, England), as recommended by themanufacturer. Fluorescein-
conjugated anti-rabbit IgG and alkaline phosphatase-conjugated or
peroxidase-conjugated anti-rabbit IgG were purchased from Sigma
(St. Louis, USA).
2.2. Site-directed mutagenesis of LiRecDT1
Cloning from the venom gland cDNA library was performed fol-
lowing the methods of Chaim et al. [12]. GenBank data deposition
information for L. intermedia cloned cDNA can be found under
LiRecDT1 (DQ218155). The cDNA corresponding to the mature
phospholipase-D original protein was ampliﬁed by PCR. The sense
primer used was 30Rec (5′-CTCGAGGCAGGTAATCGTCGGCCTATA-3′),
which was designed to contain a XhoI restriction site (underlined)
plus the sequence for the ﬁrst seven amino acids of the mature
protein. The antisense primer used was 30Rec (5′-CGGGATCCT-
TATTTCTTGAATGTCACCCA-3′), which contains a BamHI restriction
site (underlined) and a stop codon (bold). The PCR product was
cloned into the pGEM-T vector (Promega, Madison, USA), subcloned
into pET-14b (Novagen, Madison, USA) and digested with XhoI and
BamHI. The mutated toxin was obtained using the Megaprimer PCR
method adapted from Sambrook and Russell [31]. This protocol was
performed using three rounds of PCR to carry out site-directed
mutagenesis in the LiRecDT1 sequence, and the resulting mutated
toxin was named LiRecDT1 H12A. Brieﬂy, the ﬁrst round of PCR
included site-directed mutagenesis of the ﬁrst histidine amino acid
residue using the forward primer T7, which anneals to the pSPORT
vector 5′ portion, and the special reverse primer P1H12A (5′-
ATTTACCATGGCCCCCATGATC-3′), which contains the codon substi-
tute for alanine plus the sequence for the other original amino acids.
The “megaprimer” for the next round was obtained by agarose gel
electrophoresis of the ﬁrst PCR product (~200 bp) and puriﬁed using
the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany). In the
second step, PCR was performed to obtain the mutated product using
the “megaprimer” as the sense primer and 30Rec as the antisense
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subjected to the same protocol of agarose gel puriﬁcation. In the ﬁnal
step of mutagenesis, a third PCR reaction was performed to insert the
5′ XhoI restriction site from the second PCR product by using 30Rec as
the sense primer and 30Rec as the antisense primer. Finally, this last
PCR product was digested with restriction enzymes and puriﬁed
by agarose gel electrophoresis. The mutated product was then
cloned into the pGEM-T vector (Promega) and subcloned into pET-
14b (Novagen). The correct construct was conﬁrmed by miniprep
sequencing.
2.3. Original (LiRecDT1) and mutated LiRecDT1 (LiRecDT1 H12A)
recombinant toxin expression and puriﬁcation
Both recombinant constructs were expressed as fusion proteins
with a poly-(6X) His tag at the N-terminus as previously described
by Chaim et al. [12]. Brieﬂy, pET-14b/L. intermedia cDNA constructs
were transformed into One Shot E. coli BL21(DE3)pLysS competent
cells (Invitrogen). Expression conditions were standardized for
induction with IPTG (isopropyl β-D-thiogalactoside) for 3.5 h at
30 °C in 1 L of LB broth cultures. Cell suspensions were sonicated
with six 10-second cycles at low intensity, and lysed materials were
centrifuged (20,000×g, 20 min). The recovered supernatants were
incubated for afﬁnity chromatography with 1 ml of Ni2+-NTA
agarose beads for 1 h at 4 °C. Recombinant protein/beads suspen-
sions were loaded into a column and exhaustively washed until the
OD at 280 nm reached 0.01 (washing buffer: 50 mM sodium
phosphate pH 8.0, 500 mM NaCl, 20 mM imidazole). Recombinant
proteins were eluted with 10 ml of elution buffer (washing buffer,
but 250 mM imidazole). Protein expression analysis on 12.5% SDS-
PAGE was performed for purity andwas stained with Coomassie Blue
dye. For experimental negative controls, a recombinant toxin with
similar molecular mass and obtained from the same cDNA library
was used. This control toxin was characterized as an “astacin-like
metalloprotease” [32] and caused no dermonecrosis, as evidenced by
the dermonecrotic assay following injection into rabbit skin (data
not shown).
2.4. Circular dichroism spectra measurements
Recombinant original and mutated toxins were dialyzed at 4 °C
against 10 mM sodium phosphate buffer, pH 7.4, and their spectra
were recorded in a Jasco J-810 spectropolarimeter (Jasco Corporation,
Tokyo, Japan) using a 1-mm gap cuvette. Each reported spectrum
(0.5 nm interval) is the average of eight measurements performed at a
rate of 50 nm/min using a response time of 8 s and a bandwidth of
1 nm. The temperature was kept constant at 25 °C.
2.5. Phospholipase activity assay
Phospholipase-D activitywasmeasuredusing the Amplex RedAssay
Kit (Molecular Probes, Eugene, USA). In this assay, phospholipase-D
activity was monitored using 10-acetyl-3,7-dihydroxyphenoxazine
(Amplex Red reagent), a sensitive ﬂuorogenic probe for H2O2. First,
phospholipase hydrolyzes sphingomyelin to yield C1P and choline.
Choline is oxidized by choline oxidase to betaine andH2O2. Finally, H2O2
in the presence of horseradishperoxidase reactswithAmplex reagent in
a 1:1 stoichiometry to generate thehighlyﬂuorescentproduct resoruﬁn.
Recombinant toxins (10 μg each to start, in three trials; later 100, 250
and 500 μg of LiRecDT1 H12A) were added to the Amplex Red reagent
mixture to aﬁnal volume of 500 μl. The reaction tubeswere incubated at
37 °C in a water bath for 30 min and ﬂuorescence was measured in a
ﬂuorometer (Shimadzu Model RF-5301 PC Fluorescence Spectropho-
tometer) using excitation at 560 nm and emission detection at 590 nm.
The controls were LALP (loxosceles astacin-like protease) [32] for a
negative control and whole venom for a positive control. Sphingomy-elinase (0.004 U) from Bacillus cereus (1 U=1 μmol min−1) was co-
tested, and ﬂuorescence intensity was used as standard for comparing
ends. Fluorescence intensity values were converted to units of
phospholipase activity, which were expressed as μmol min−1 (amount
of substrate hydrolyzed per minute).2.6. Animals
Adult rabbits weighing approximately 3 kg obtained from the
Central Animal House of the Federal University of Paraná were used
for in vivo experiments with recombinant toxins. All experimental
protocols using animals were performed according to the “Principles
of laboratory animal care” (NIH Publication no. 85-23, revised 1985)
and the “Brazilian Federal Laws” as well as the ethical committee
agreement number 246 of the Federal University of Paraná.2.7. Dermonecrosis in vivo
For the evaluation of dermonecrotic effects, 10 μg of each toxin
was injected intradermally into a shaved area of the rabbit skin for the
ﬁrst experiments. Animals were observed over the course of
dermonecrotic lesion evolution. The LiRecDT1 H12A residual activity
experiment was performed under the same conditions, except that
doses were increased to 100, 250, and 500 μg of mutated toxin.
Acquisition of macroscopic pictures was performed after 4 h and 24 h
of toxin application, and skin samples were collected at the end of the
experiment for microscopic analysis and myeloperoxidase (MPO)
activity assay.2.8. Tissue MPO activity assay
The activity of tissue MPO was also assessed 24 h after injection of
toxins into the rabbit skin, according to a technique modiﬁed from
Bradley et al. [33,34]. Brieﬂy, samples were placed in 0.75 ml of
80 mM phosphate-buffered saline (PBS), pH 5.4, containing 0.5%
hexadecyltrimethylammonium bromide, and then homogenized
(45 s at 0 °C) in a motor-driven homogenizer. The homogenate was
decanted into a microfuge tube, and the vessel was washed with
0.75 ml of hexadecyltrimethylammonium bromide in buffer. The
washwas added to the tube, and the 1.5-ml sample was centrifuged at
12,000×g at 4 °C for 15 min. Triplicate 30 μl samples of the resulting
supernatant was added to 96-well microtiter plates. For the assay,
200 μl of a mixture containing 100 μl of 80 mM PBS, pH 5.4, 85 μl of
0.22 M PBS, pH 5.4, and 30 μl of 0.017% hydrogen peroxide was added
to the wells. The reaction was started with the addition of 20 μl
18.4 mM tetramethylbenzidine HCl in dimethylformamide. Plates
were incubated at 37 °C for 10 min, and then the reactionwas stopped
by the addition of 30 μl of 1.46 M sodium acetate, pH 3.0. Enzyme
activity was determined colorimetrically using a plate reader (EL808,
BioTech Instruments, Inc.) set to measure absorbance at 630 nm and
was expressed as mOD/mg tissue.2.9. Histological procedure for light microscopy
Skin samples were collected from rabbits anesthetized with ke-
tamine (Agribands, Paulinia, Brazil) and acepromazine (Univet, São
Paulo, Brazil) and then ﬁxed in Bouin's ﬁxative solution (picric acid
saturated solution, 750 ml; formaldehyde 36–40%, 250 ml; acetic acid,
50 ml) for 16 h at room temperature. After ﬁxation, samples were
dehydrated in a graded series of ethanol before being parafﬁn
embedded (for 2 h at 58 °C). Then, thin tissue sections (4 μm) were
processed and stained with hematoxylin and eosin (H&E).
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The protein content of experimental samples was determined by
the Coomassie Blue method (BioRad, Hercules, USA). For immuno-
blotting, 5 μg of each toxin was subjected to 12.5% SDS-PAGE under
reducing conditions, transferred onto nitrocellulose ﬁlters over-
night and immunostained with hyperimmune sera (either against
phospholipase-D toxin or whole venom). Secondary alkaline
phosphatase-coupled anti-IgG were detected and visualized using
the BCIP/NBT substrate reaction. For the antibody capture assay
(ELISA), tests were performed in pentaplicate with 10 μg/ml of
venom and LiRecDTs toxins as antigens. Puriﬁed hyperimmune IgGs,
anti-LiRecDT1, and anti-whole venom were tested (0.1–1 μg/ml),
followed by detection with secondary peroxidase-coupled anti-IgG
and reading of the absorbance at 450 nm for the OPD substrate
reaction [35].
2.11. Protein–lipid overlay assay (fat blot)
The afﬁnity of toxins for speciﬁc lipids was tested using the
SphingoStrips recommended method (Molecular Probes, Eugene,
USA). In summary, nitrocellulose membranes containing 100 pmol
samples of 15 different lipids and a blank sample were blocked using
Tris-buffered saline plus 0.02% Tween-20 (TBS-T) with 3% fatty acid-
free bovine serum albumin (BSA) and gently agitated for 1 h at room
temperature. Then, the membranes were incubated with 0.5 μg/ml of
the toxins (whole venom, LiRecDT1, or LiRecDT1 H12A) in TBS-T plus
3% BSA at 4 °C overnight. Membranes were then washed with TBS-T
plus 3% BSA three times for 10 min using gentle agitation. Toxin
binding was detected using anti-venom or anti-LiRecDT1 puriﬁed
IgGs and revealed by alkaline phosphatase-labeled secondary anti-
bodies and BCIP/NBT substrate.
2.12. Cell culture conditions
RAEC (rabbit aorta endothelial cells) were grown as monolayer
cultures in F12 medium containing gentamicin (40 mg/L) supple-
mented with 10% fetal calf serum (FCS). The cultures were kept at
37 °C in a humidiﬁed atmosphere with 5% CO2. For inverted light
microscopy observation and confocal immunoﬂuorescence analysis,
release of cells was performed by treatment with 0.25% viokase/HBSS
for a few minutes. After counting, the cells were resuspended in an
adequate volume of medium supplementedwith FCS, and 5×103 cells
were replated on glass coverslips (13 mm diameter) and allowed to
adhere and grow for 48 h. The cells were then incubated in the
presence of the recombinant toxins (10 μg/ml). Changes in cell
morphology were evaluated and photographed using an inverted
microscope (Leica-DMIL, Wetzlar, Germany) at 1 h and 4 h after
recombinant toxin addition. The same experimental conditions were
used with control cells, except that the medium contained appropri-
ate amounts of vehicle (PBS) instead of recombinant toxins.
2.13. RAEC immunoﬂuorescence assay
For immunoﬂuorescence microscopy, after recombinant toxins
exposure for 4 h at 37 °C, RAEC cells were rapidly washed with PBS,
ﬁxed with 2% paraformaldehyde in PBS for 30 min at 4 °C, incubated
with 0.1 M glycine for 3 min, and blocked with PBS containing 1% BSA
for 1 h at room temperature. Coverslips were incubated for 1 h with
polyclonal antibodies raised against phospholipase-D (2 μg/ml) as
described in the Reagents section. Cells were washed three times with
PBS, blocked with PBS containing 1% BSA for 30 min at room
temperature, and then incubated with Alexa® 488-conjugated anti-
rabbit IgG secondary antibodies (Molecular Probes) at room temper-
ature for 40 min. After washing, samples were mounted using
Fluormont-G (Sigma) and observed under a ﬂuorescence confocalmicroscope (Confocal Radiance 2100, BioRad) coupled to a Nikon-
Eclipse E800 with Plan-Apochromatic objectives (Sciences and
Technologies Group Instruments Division, Melville, USA).2.14. Choline release detection from RAEC cell extract
Extracts of RAEC cell membranes were obtained from approxi-
mately 5×106 cells (150 cm3 culture bottle). Cells were scraped and
resuspended in 1 ml of cold extraction buffer (Tris–HCl 50 mM, NaCl
150 mM, Triton X-100 0.5%). After gently homogenizing for 10 min at
4 °C, cells were centrifuged at 20,000×g for 20 min at 4 °C and
supernatants were collected for later use. RAEC cells extracts (100 μl)
were utilized as a substrate for LiRecDT1 and LiRecDT1 H12A (both in
two concentrations, 50 μg and 100 μg) in a total ﬁnal volume of 250 μl
for 1 h at 37 °C and gently mixed using a rotational shaker in a BOD
incubator. Treated extracts were then added to a 250 μl reaction
mixture adapted from the Amplex Red Sphingomyelinase Assay Kit
(Molecular Probes) containing choline oxidase (4 U), alkaline phos-
phatase (80 U), horseradish peroxidase (20 U), and Amplex Red
reagent (100 μM), excluding sphingomyelin substrate. After incuba-
tion in a water bath for 1 h at 37 °C, ﬂuorescence development was
measured in a ﬂuorometer (Shimadzu Model RF-5301 PC Fluores-
cence Spectrophotometer) using excitation set at 560 nm and
emission detection at 590 nm.2.15. Lipid analysis by high-performance thin-layer chromatography
For analysis of hydrolysis, recombinant toxins (50 μg) were
incubated with RAEC cell extracts (50 μl or 100 μl) for 3, 8 or 16 h,
and puriﬁed phospholipids for 3 h at 20 °C. Lipids present in these
detergent-soluble samples were recovered directly by partition with
2 ml of water-saturated 1-butanol; the butanol fraction was dried,
resuspended in chloroform, and analyzed by high-performance thin-
layer chromatography (HPTLC). Analytical HPTLC was performed on
silica gel 60 plates (E. Merck, Darmstadt, Germany) using chloroform–
methanol–methylamine 40% (65:35:10 v/v/v) as the mobile phase.
Lipid samples were dissolved in chloroform and 20 μl were applied by
micropipetting, and then visualized under ultraviolet light after
spraying with 0.01% primulin in 90% aqueous acetone [36]. Differ-
ences in lipid content were quantiﬁed by densitometry of digital
images from HPTLC plates acquired by GeneSnap Software for G:Box
Chemi XL (Syngene, Cambridge, England) and quantiﬁed by Quantity
One Software for Chemic Doc XRS (BioRad, Hercules, USA). The
standard mixture contained 1 mg/ml each of ﬁve phospholipids
(Sigma): phosphatidylinositol (PI), phosphatidylcholine (PC), phos-
phatidylethanolamine (PE), and phosphatidylserine (PS). Toxins were
also incubatedwith 10 μg of puriﬁed phospholipids: asymmetric PC or
16:0–18:0 PC (1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine),
and PAF platelet-activating factor or C16-2:0 PC (1-O-hexadecyl-
2-acetoyl-sn-glycero-3-phosphocholine), and synthetic alkyl-
phospholipids such as lysoPC or 16:0 Lyso PC (1-palmitoyl-2-hydroxy-
sn-glycero-3-phosphocholine) and lysoPAF or C16 Lyso PAF (1-O-
hexadecyl-2-hydroxy-sn-glycero-3-phosphocholine). Puriﬁed egg
chicken sphingomyelin (egg SM) and other phospholipids tested were
purchased from Avanti Polar Lipids, Inc. (Alabaster, USA).2.16. Statistical analysis
Statistical analysis of phospholipase activity and choline release
data were performed using analysis of variance (ANOVA) and the
Tukey test for average comparisons GraphPad InStat program version
3.00 for Windows. Mean±SEM. values were used. Signiﬁcance was
determined as p≤0.05.
Fig. 1. Expression of a functional recombinant site-directed mutated dermonecrotic
protein (LiRecDT1 H12A). (A) SDS-PAGE analysis of recombinant dermonecrotic
toxin expression stained with Coomassie blue dye (12.5% gel under reducing
conditions). Lanes 1 and 2 show E. coli BL21(DE3)pLysS cells collected by
centrifugation and resuspended in gel loading buffer before and 3.5 h after induction
with 0.05 mM IPTG, respectively. Lanes 3 and 4 depict the supernatant of cell lysates
obtained by freeze thawing in extraction buffer before and after (void) incubation
with Ni-NTA agarose beads, respectively. Lane 5 shows eluted recombinant protein.
Molecular masses are shown on the left. (B) Circular dichroism spectra for the
puriﬁed recombinant original and mutated toxins. Spectra were obtained using
toxins in 10 mM sodium phosphate buffer, pH 7.4, at 25 °C. Molar ellipticity was
analyzed in a wavelength range between 180 and 260 nm. (C) Phospholipase-D
activity of recombinant toxins. Sphingomyelinase activities of LiRecDT1, LiRecDT1
H12A recombinant toxins, and whole venom were evaluated with the Amplex Red
Assay Kit at 37 °C for 1 h; the product of the reaction was spectroﬂuorimetrically
measured at 560 nm excitation and 590 nm emission wavelengths. A puriﬁed
recombinant toxin without dermonecrotic and inﬂammatory activities was used as a
negative control. Reactions were performed with 10 μg of whole venom or
recombinant toxins (n=6). Values given are the average±SEM.
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3.1. Cloning and expression of a mutated dermonecrotic toxin from
LiRecDT1: drastic decrease of phospholipase-D activity by a single amino
acid mutation
In order to obtain a mutated form of L. intermedia dermonecrotic
toxin, an adapted “Megaprimer” PCR approach for site-speciﬁc
mutation was used to clone a mutated dermonecrotic toxin based
on the LiRecDT1 (GenBank accession number ABA62021) amino acid
sequence [12]. This recombinant toxin contained an amino acid
sequence that was substituted with alanine at the ﬁrst histidine
residue (His12), which plays a role in the catalytic reaction. Alteration
of the active site was conﬁrmed by sequencing analysis, and the
resulting LiRecDT1 H12A mutated recombinant toxin was suc-
cessfully expressed in the pET-14b system and puriﬁed in soluble
form by Ni2+-NTA afﬁnity chromatography (Fig. 1A). To insure the
correct folding of the mutated toxin occurred despite the changed
nucleotide sequence, which codes for a different protein sequence,
conformational circular dichroism spectra measurements were
performed. Indeed, we observed a secondary structure spectrum for
the mutated form that was very similar to the LiRecDT1 CD proﬁle as
depicted in Fig. 1B. To investigate the enzymatic behavior of the
mutated LiRecDT1 H12A phospholipase-D toxin in vitro, a ﬂuoromet-
ric assay using sphingomyelin as the reaction substrate was
performed (see Materials and methods section for details). LiRecDT1
and whole venom showed the expected high phospholipase-D
activity [12], but the mutated toxin had almost no sphingomyelin
hydrolysis activity under the same conditions. Fig. 1C shows that the
activity of 10 μg of recombinant original toxin was about 85-fold
higher than that of the mutated toxin.
3.2. LiRecDT1 H12A did not induce dermonecrosis in rabbit skin and
caused only a small inﬂammatory reaction
Dermonecrotic macroscopic development was observed in rabbit
skin after 4 h and 8 h of exposure to 10 μg of whole venom (as a
positive control) and original recombinant dermonecrotic toxin.
However, treatment with the mutated form did not cause obvious
dermonecrotic development, and the reaction was similar to the
negative control (see Experimental). In addition, no edema or
erythema was observed at the injection site in response to the
mutated form (Fig. 2A). Light microscopic analysis of rabbit skin
biopsies after 24 h of toxin treatment (Fig. 2B) demonstrated typical
intense inﬂammatory cell accumulation and collagen ﬁber disorgani-
zation in the dermis with LiRecDT1 treatment. However, biopsy
analysis of LiRecDT1 H12A exposed skin demonstrated a less intense
inﬂammatory response. The neutrophil migration into the dermis was
indirectly determined by means of MPO activity of tissue biopsies
(Fig. 2C), and the differences in these values correlate with the
microscopic analysis of inﬂammatory reaction.
3.3. The residual activity of LiRecDT1 H12A is concentration-dependent
As the microscopic analysis revealed an inﬂammatory reaction in
rabbit skin treated with mutated recombinant toxin, it is possible that
very low phospholipase-D activity persists despite modiﬁcation of
His12A in the catalytic site. This residual activity could be responsible
for the observed biological effects. For this reason, phospholipase-D
activity and dermonecrosis analysis of LiRecDT1 H12Awere examined
again at much higher concentrations. Higher amounts of LiRecDT1
H12A (100 μg, 250 μg, and 500 μg) were used in both experiments
with the previously described conditions (Fig. 3). A 2.4-fold increase
in phospholipase activity was observed between 100 and 500 μg
protein. The phospholipase-D activity of the highest concentration
tested (500 μg) compared to 10 μg of original recombinant toxin wasstill 7-fold less intense (Figs. 1C and 3A). Moreover, Fig. 3B depicts in
vivo experiments showing formation of edema and erythema at the
injection site that weremuch less intense compared to those observed
with LiRecDT1 after 4 h. At 24 h post LiRecDT1 H12A exposure, rabbit
skin showed more edema, and an initial white eschar, known as a
marble plate in loxoscelism (that commonly evolves into necrotic
lesion) could be seen. Microscopic analyses (Fig. 3C) of biopsies from
Fig. 2. Dermonecrosis and inﬂammatory response of rabbit skin exposed to recombinant toxins. (A) Macroscopic visualization of dermonecrosis of rabbits intradermally injected
with 10 μg of whole venom (as positive control) or both recombinant toxins. Lesions were observed 4 and 24 h following venom and recombinant toxin injections. Arrows point to
development of gravitational spreading of necrotic lesion post LiRecDT1 and whole venom injections. The scale bar is shown on the left. (B) Histopathological ﬁndings for rabbit skin
were performed 24 h after recombinant toxin exposure. Light microscopic analysis of tissue sections were assessed by staining with hematoxylin and eosin (H&E). An intense
inﬂammatory response with the presence of neutrophils and disorganization of collagen ﬁbers in connective tissue is shown for the original toxin compared to a lower inﬂammatory
reaction observed following mutated recombinant dermonecrotic toxin exposure. A recombinant toxin without phospholipase-D activity but obtained under identical conditions
was used as a negative control (magniﬁcation 630×). (C) Inﬂammatory reactions induced by toxins and controls were estimated by measurement of myeloperoxidase activity from
neutrophil inﬁltrate at the dermis. Values are expressed as mean±SEM of absorbance at 630 nm. Each bar represents the mean of ﬁfteen replicates (ﬁve from each of three tissue
samples) of inoculation site at rabbit skin post 24 h. The asterisk denotes the signiﬁcance levels when compared with negative control (*** pb0.001; ** pb0.01).
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showed an abundant neutrophil perivascular inﬁltrate and collapse of
blood vessel walls into the dermis.3.4. Immunological cross-reactivity of original and mutated LiRecDTs
In order to determine whether antigens of our antibodies are
conserved in the recombinant LiRecDT1 and LiRecDT1 H12A, we
produced polyclonal antisera against whole venom and LiRecDT1.
Whole venom served as the positive control for native phospholipase-
D toxins, which were also recognized by both antisera. Experiments
were performed by Western blot (antibodies recognize epitopes on
denatured antigens) and ELISA (antibodies recognize non-denatured
epitopes on antigens). The cross-immunoreaction of antisera for both
recombinant toxins showed that site-directed mutation did not alter
immunological recognition by polyclonal antibodies; therefore, these
antibodies can be used for further experiments (Fig. 4).3.5. Binding of both recombinant toxins to immobilized lipids in an
overlapping assay
Fat blot assays are used for the identiﬁcation of proteins possessing
lipid recognition domains and for analysis of their lipid-binding
speciﬁcities. Several different toxin interactions were detected via the
protein–lipid overlay assay with a standard Western blot. These
interactions have been shown to be involved in physiological and
pathological processes including signal transduction mediated by
GPCRs and induction of apoptosis [18–20,37,38]. With the goal of
determining whether dermonecrotic toxin possesses some lipid
afﬁnity, we exposed the original and mutated isoform to immobilized
lipids (Fig. 5). Additionally, we tested whole venom as a control to test
native dermonecrotic toxins. Both recombinant isoforms bound to the
same molecules: sphingomyelin and sphingosine 1-phosphate,
phosphatidylcholine and lysophosphatidylcholine, and cholesterol.
As a negative control, the membrane containing immobilized lipids
was exposed to antibodies in the absence of toxins (data not shown).
Fig. 3. Residual phospholipase-D and inﬂammatory activities of LiRecDT1 H12A. (A) Mutated recombinant toxin was tested for persistent sphingomyelinase activity with increasing
doses of 100, 250, and 500 μg. Then, the Amplex Red Sphingomyelinase Assay Kit assay was performed using the same conditions and incubating at 37 °C for 1 h. Reactions were
measured in a spectroﬂuorometer (wavelengths of 560 nm for excitation and 590 nm for emission). As a negative control, 10 μg of enzymatic non-related recombinant toxin was
also tested to assess background ﬂuorescence. Increasing concentration-dependent phospholipase-D activity was observed (n=6). Values given are the average±SEM.
(B) Macroscopic analysis of rabbit skin exposed to higher concentrations of LiRecDT1 H12A. In a dose-dependent reaction, we observed a punctate and transient erythema at the
injection site 4 h post exposure to mutated toxin exposure (100, 250, and 500 μg). After 24 h, development of an ischemic halo surrounding the injection site indicates typical and
initial formation of dermonecrosis described as a marble plate, and (C) microscopic analysis of tissue sections by H&E show a large inﬂammatory response with massive neutrophil
diapedesis and ﬁbrin deposition at disrupted blood vessels for all three concentrations tested (magniﬁcation 630×).
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3.6. Recombinant dermonecrotic toxins bind to the RAEC cell surface as
“planted antigens”
We next examined the cell membrane interaction of the dermo-
necrotic toxin phospholipase-D family speciﬁcally, as whole venom is
a complex mixture of biochemically and biologically different toxins.
To do this, we evaluated recombinant dermonecrotic toxin binding to
the endothelial cell surface using hyperimmune IgGs against LiRecDT1
by confocal immunoﬂuorescence analysis (Fig. 6). Cells treated with
both recombinant toxins showed an intense positive reaction on the
cell surface. Untreated cells (negative control) were treated to conﬁrm
that there was no non-speciﬁc binding of the hyperimmune
antibodies. The interaction of toxins with RAEC cell membranes had
a homogeneous distribution pattern. Again, LiRecDT1 H12A was also
able to bind to the plasma membrane (an environment enriched in
lipids) despite the mutation in the catalytic site.
3.7. Choline release from RAEC cell membrane extracts with LiRecDT1
treatment
Since the appearance of cluster-like aggregates were observed on
RAEC cell membranes only after LiRecDT1 but not mutated toxin
treatment, we examined whether cell membrane RAEC extracts couldact as an enzymatic substrate for phospholipid hydrolysis. The original
substrate used for the sphingomyelinase activity kit test (a puriﬁed
sphingomyelin) was substituted with cell membrane detergent
extract obtained from RAEC cells in culture (see Materials and
methods for details). Therefore, not only sphingomyelin, but also
other phospholipids from RAEC cell extracts could be the target of
phospholipase-D. Incubation of recombinant toxins with extracts
triggered signiﬁcant formation of choline in response to LiRecDT1 in a
concentration- and time-dependent manner (Fig. 7A). Changes in cell
morphology triggered by LiRecDT1, such as cytoplasmic vacuolization
and the presence of debris resulting from cell lysis were observed
(Fig. 7B). These results suggested that phospholipase-D activity on
membrane phospholipids correlates directly with cytotoxicity.
3.8. LiRecDT1 degrades lipids from RAEC cell membrane extracts and
puriﬁed phospholipids
In addition to the phospholipase-D activity indirectly shown by
choline release, hydrolysis of RAEC cell membrane extracts can be
observed through high-performance thin-layer chromatography
(HPTLC). Fig. 8A and B shows that after incubation with both
LiRecDT1 and LiRecDT1 H12A, the intensity of primuline-positive
bands decreased compared to non-treated extract control. With 50 μl
of extracts, the band for phosphatidylethanolamine was gradually
reduced to a ﬁnal relative quantity of 37% after 16 h with active
phospholipase-D. However, the mutated isoform was able to degrade
Fig. 4. Immunological cross-reactivity of the recombinant toxins LiRecDT1 and LiRecDT1 H12A. Original (DT1) and mutated (H12A) toxins at a concentration of 10 μg were
electrophoresed by 12.5% SDS-PAGE under reducing conditions, transferred to nitrocellulose membranes, and incubated with puriﬁed IgGs from sera recognizing whole venom or
LiRecDT1. Immunoblotting was performed with secondary antibodies coupled to alkaline phosphatase and BCIP/NBT substrate. Additionally, antibody capture assays (ELISA) were
carried out using whole venom and recombinant toxins LiRecDT1 and LiRecDT1 H12A (10 μg/ml) immobilized on a solid phase. Again, puriﬁed antibodies against whole venom or
LiRecDT1 (abscissa) were incubated for 2 h at room temperature and the immunoreaction was performed using secondary antibodies coupled to peroxidase and OPD substrate.
Colorimetric measurement was performed by absorbance at 450 nm. Values given are average of pentuplicates.
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extracts but the same concentrations of recombinant toxins, bands for
other lipids such as sphingomyelin and phosphatidylcholine are
visible and show drastic intensity decreases. Speciﬁcally, SM was
reduced to 5.6% and PC to 13.0% of the control. Interestingly, the
mutated isoform of phospholipase-D was able to signiﬁcantly degrade
SM after 16 h to less than a half of initial content (41.1%), but the same
was not observed for PC, which was only reduced to approximately
87.2% of control. The bands for phosphatidylserine were also reduced
by both toxins, to 58.9% and 63.2% of control for LiRecDT1 and
LiRecDT1 H12A, respectively. Next, we tested puriﬁed phospholipids
individually (Fig. 8C and D) and found that 3 h after incubation, egg
sphingomyelin and lysoPC were most susceptible to hydrolysis by
recombinant toxins from L. intermedia with a reduction to 6.2% and
4.9% of control, respectively. The H12A mutation did not completely
abolish its enzymatic ability, as the mutated toxin hydrolyzed
both phospholipids but with lower effectiveness (77.0% and 59.2%,Fig. 5. Lipid binding of venom toxins in fat blot assays. Each spot contains 100 pmol of th
recombinant toxins, which were incubated at a concentration of 0.5 μg/ml with the membran
same spotted lipids: sphingosine 1-phosphate and sphingomyelin, lysophosphatidic acid, ch
the toxins was detected using puriﬁed IgGs against whole venom or against LiRecDT1, an
substrate.respectively). In addition, PC asymmetric, PAF and lysoPAF were also
degraded by the toxins, but more signiﬁcantly by the original than
the mutated isoform. These results suggest that brown spider
phospholipase-D has no speciﬁcity for one single type of lipid as a
substrate/target. Lipid-derived products can be visualized at the top of
those lanes with intense decrease of initial lipid content (*). Puriﬁed
sphingomyelin and lysophospholipids were the best substrates of this
enzyme, but after only 3 h of incubation other non-lysophospholipids
were also signiﬁcantly degraded. These were also observed in HPTLC
with cell membrane extracts.
4. Discussion
Loxoscelism is characterized as a group of severe clinical symptoms
triggered by brown spider (Loxosceles genus) bites. Brown spider bites
can induce dermonecrotic lesions, hematological disorders, and renal
failure [1,2]. Histopathological ﬁndings for rabbit skin experimentallye indicated lipid in the layout of strips used to test the afﬁnity of whole venom and
es. Samples of whole venom, LiRecDT1, and LiRecDT1 H12A show overlapping with the
olesterol, and both lysophosphatidylcholine and phosphatidylcholine. Lipid binding of
d revealed with secondary antibodies coupled to alkaline phosphatase and BCIP/NBT
Fig. 6. Recombinant dermonecrotic toxin binding to RAEC cell membranes. Confocal
immunoﬂuorescence microscopy analysis was performed for both LiRecDT1 and
LiRecDT1 H12A-treated endothelial cells incubatedwith antibodies anti-LiRecDT1 and a
speciﬁc secondary ﬂuorescent conjugate. (A) Four hours post-incubation of Original
toxin (40 μg/ml), the cell surface showed punctate binding of LiRecDT1 (arrowheads)
and deposition as aggregated clusters (arrows). (B) LiRecDT1 H12A treatment (40 μg/
ml) also caused non-homogeneous binding of the mutated toxin (arrowheads), but no
cell membrane aggregation was visualized. The scale bar is visualized on the left.
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walls, endothelial cytotoxicity, and ﬁbrin and thrombus formation
[6,7]. Likewise, capillary hyperpermeability and intense inﬁltration of
polymorphonuclear leukocytes around blood vessels cause a massive
inﬂammatory response to the venom toxins [2,11].
Brown spider venom is a complex mixture of biochemically and
biologically varied toxins reported by proteomic analysis to have
molecular masses predominantly in the range of 3–40 kDa [39–41].
Most reported biological effects can be reproduced by dermonecrotic
toxin family members (phospholipases-D). Previous reports have
shown that a recombinant dermonecrotic toxin from the L. intermedia
venom gland (LiRecDT1) was capable of stimulating dermonecrosis,
hemolysis, platelet aggregation, renal disturbance, increased vas-
cular permeability, and a deregulated inﬂammatory activation [11–
13,15,41].
Futrell [2] has characterized dermonecrotic toxin as a
sphingomyelinase-D enzyme because of its ability to hydrolyze
sphingomyelin into choline and acylsphingosine phosphate. Recently,
Lee and Lynch [10] suggested the term sphingomyelinase-D should
be replaced by phospholipase-D to better classify brown spider der-
monecrotic toxins based on their additional ability to hydrolyze
glycerophospholipids. As such, the formation of lipid metabolites (also
known as potent bioactive molecules) such as C1P or LPA could be
responsible for the toxicity by activating signaling pathways related to a
variety of pathophysiologic changes [10,18,20].
In this work, we investigated the dependence of the enzymatic
activity of phospholipase-D to evoke the toxicity displayed in response
to the biological effects of brown spider dermonecrotic toxin. To this
end, we produced a mutated form of the dermonecrotic toxin from
L. intermedia venom. The previously described LiRecDT1 wasmodiﬁed
at the catalytic site with a single amino acid change using a site-
directed mutagenesis strategy. In the literature, several studies haveused the mutation of speciﬁc amino acid residues to evaluate the
structure and function of toxins [42,43]. Kukreja et al. [44] examined
the molecular action of botulinum neurotoxin endopeptidase by
substitutingGlu262with Asp and showed a 3-fold decrease in catalytic
efﬁciency. This mutation did not induce any signiﬁcant structural
alterations in the active site and did not interfere with substrate
binding.
Based on a study of the crystal structure of L. laeta dermonecrotic
toxin (SMaseI) [17], the proposed acid base catalytic mechanism
postulated residues His12 and His47 as playing key roles and being
supported by a network of hydrogen bonds between Asp34, Asp52,
Trp230, Asp233, and Asn252. We chose the ﬁrst histidine residue
(His12) in the catalytic site as a mutation target, intending to abolish
phospholipase-D activity of the resulting toxin.
Recombinant expression of the mutated toxin as a fusion protein
was successfully achieved (Fig. 1A and B) and we named it LiRecDT1
H12A (Loxosceles intermedia dermonecrotic toxin 1, mutation at His12
to Ala residue). To conﬁrm the effectiveness of the site-directed
mutation in extinguishing phospholipase-D activity, we performed
classic tests for characterizing dermonecrotic toxin: sphingomyelin
hydrolysis in vitro and dermonecrosis in vivo [1,2]. Compared to 10 μg
of the original toxin and whole venom, LiRecDT1 H12A presented
insigniﬁcant phospholipase-D activity and no macroscopic effect on
rabbit skin (Fig. 1C). Meanwhile, histopathological ﬁndings for the
LiRecDT1 H12A tissue samples showed the presence of a neutrophil
inﬁltrate and collagen ﬁber disorganization in the treated rabbit skin
(Fig. 2B). Despite this controversial ﬁnding, we presume that
LiRecDT1 H12A did not lose phospholipase-D activity completely.
Indeed, residual enzymatic activity was observed by testing higher
concentrations of the mutated toxin (Fig. 3). The phospholipase-D
activity of 500 μg of the mutated toxin increased compared to 10, 50,
and 100 μg, but was considerably lower than 10 μg of the original
toxin, suggesting some residual catalytic activity of the protein.
Cross-reactivity experiments demonstrated that antibodies
against venom or LiRecDT1 can also recognize linear (Fig. 4) and
conformational epitopes (Fig. 4) of LiRecDT1 H12A. As a result, the
mutated toxin could be used as a biological tool for comparing
identical proteins with almost insigniﬁcant enzymatic activity that is a
structural analogue for dermonecrotic toxin. First, anti-toxin hyper-
immune IgGs were used to reveal the binding of LiRecDT1 to speciﬁc
lipids immobilized in nitrocellulose (Fig. 5). Protein–lipid overlapping
experiments are in vitro reproductions of biological events triggered
by protein interactions with lipid domains on the plasma cell
membrane. Recombinant original and mutated toxins bound to the
same lipids, including sphingomyelin and phosphatidylcholine.
The His12Ala modiﬁcation in the amino acid sequence of re-
combinant dermonecrotic toxin did not interfere with its lipid-
binding property. LiRecDT1 may be interacting by a linear or con-
formational region in the molecule independently of catalytic activity
or even the active site domain. It has beenwell described that proteins
expose hydrophobic surfaces of their molecular structures, allowing
them to bind phospholipids on the cell membrane and trigger various
biological effects [45,46]. LiRecDT1 contains 42.6% hydrophobic
residues in its amino acid sequence. Several short sequences show
conserved hydrophobicity in LiRecDT1 (AILMFPWYV) and L. laeta
SMase I (AY093599) based on amino acid sequence alignment.
Structural analysis of recombinant dermonecrotic toxin from SMase
I [16,17] has shown that hydrophobic loops participate in the
interfacial region of the enzyme where the active site is located in a
shallow cleft.
Hydrophobic domains in the secondary and tertiary structure of
brown spider dermonecrotic toxin probably play a role in its ability to
bind lipids on the cell membrane independent of enzymatic activity
but not necessarily unrelated to the active site of LiRecDT1. Metal-
coordination and charged residues in the catalytic domain must be
important for targeting phospholipids in a hydrophilic environment
Fig. 7. Choline release induced by recombinant toxins from hydrolysis of membrane extracts as well as cytotoxic effects on endothelial cell cultures. (A) Detergent-extracts of RAEC
cell membranes (100 μl) were incubated with LiRecDT1 or LiRecDT1 H12A (abscissa depicts both toxins used at concentrations of 50 μg or 100 μg) for 1 h and 4 h in a 37 °C water
bath. Choline formation was detected using a reaction mixture adapted from the Amplex Red Sphingomyelinase Assay Kit (see Materials and methods). Degradation of cell
membrane extracts by toxins results in indirect detection of a ﬂuorescent product that was measured in a spectroﬂuorometer using an excitation at 560 nmwith emission detection
at 590 nm. (B) Using inverted light microscopy, morphological changes in RAEC cells were observed following incubation of recombinant toxins (10 μg/ml) and images were
captured at 1 h and 4 h after exposure. First, LiRecDT1 triggered vacuolization of the cell cytoplasm, which is accompanied by cell lysis and alteration of cellular adhesion to other
neighboring cells and substrate. Despite this, LiRecDT1 H12A does not seem to induce a signiﬁcant change in treated-cells. Control cells, which received adequate amounts of vehicle
(PBS) instead of recombinant toxins, displayed typical RAEC cell morphology throughout the experimental procedure.
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a prediction for the interaction of alpha-toxin (a phospholipase C from
Clostridium perfringens) with cell membranes has revealed two
different domains: calcium mediated recognition of phospholipids
head groups at the active site (amino-terminal region) and interaction
of hydrophobic amino acids with the phospholipid tail group. These
domains are structurally similar to phospholipid-binding domains in
eukaryotic proteins (carboxy-terminal region) [47].
Structure function analysis of LiRecDT1 H12A supports this
hypothesis because the same lipid afﬁnity was observed via the fat
blot assay despite almost insigniﬁcant enzymatic activity. The binding
of both toxins was also maintained as demonstrated in treated RAEC
cells (as “planted antigens”) and immunoﬂuorescence experiments.
Recently, in biological approaches with recombinant toxin treated
mice, Kusma et al. [28] showed that a mutated isoform binds to
intrinsic renal structures as well as the LiRecDT1.
The anti-toxin antibody assays showed the same non-homogeneous
pattern for the interaction of both toxins with the RAEC cell surface
(Fig. 6). Both recombinant toxins seem to be aggregated throughout the
RAEC surface, binding to speciﬁcmicrodomains in the cell membrane. Anumberof toxins suchasbacterial andviralpathogens are able toexploit
cholesterol and/or lipid rafts to gain a “foot hold” on their target hosts
[48]. Leukotoxin (Ltx) is a bacterial protein toxin from Actinobacillus
actinomycetemcomitans that induces Ca2+ ﬂuxes, mobilizing clusters of
LFA-1 (surface antigen of innate and adaptive immune cells) to lipid
rafts. Ltx utilizes the raft to stimulate an integrin signaling pathway that
results in target cell responses thatmimic ‘outside-in’ activation signals,
leading to apoptosis of target cells [49] but no change in lipid raft
content.
Moreover, direct cytotoxicity was observed after LiRecDT1 exposure
by changes in morphology of RAEC cell cultures (Fig. 7A). Vacuolization
of the cytoplasm, cell lysis debris, and alteration of cell–cell and cell–
substrate adhesion were induced in a time-dependent manner by
LiRecDT1 toxin treatment. The response of RAEC cells to LiRecDT1H12A
was very similar to untreated cells (negative control). The direct cell
membrane interaction with dermonecrotic toxins does not presuppose
cytotoxic effects, as this only occurswhen signiﬁcant enzymatic activity
is present. Likewise, morphological changes in MDCK cells and
proteinuria and renal tissue damage in mice were only triggered by
recombinant phospholipase-D with intact enzymatic activity [28].
Fig. 8. HPTLC analysis of hydrolysis of RAEC cell membrane extracts and puriﬁed phospholipids by recombinant toxins. Triton X-100 extracts from endothelial cell cultures were
incubated with 50 μg of either LiRecDT1 (T) or its mutated isoform, LiRecDT1 H12A (M), and non-treated extracts were used as control (C), for 3, 8, and 16 h. (A) Recovered lipids
post-butanol extraction were visualized by primuline reagent in HPTLC plates, as described inMaterials andmethods. (C) After 3 h of incubation with toxins, puriﬁed lipids were also
submitted to HPLC; egg chicken sphingomyelin (egg SM), asymmetric phosphatidylcholine C16:0–18:0 (PC), lysophosphatidylcholine (lysoPC), C16-2:0 PC (PAF), C16 Lyso PAF
(lysoPAF). (B and D) Band intensities were estimated densitometrically and were plotted as percentage of relative quantity, comparing with respective control samples (100%).
Percentage values are shown in the table (B), HPTLC bands of cell extracts lipid content were compared with migration patterns of phospholipids in the standard mixture (PE:
phosphatidylethanolamine, PC: phosphatidylcholine, SM: sphingomyelin, PS: phosphatidylserine).
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glycerophospholipids generates (lyso)phosphatidic acid, and the
degradation of sphingolipids forms ceramide. This reaction frees a
headgroup, such as choline (resulting, for example, from sphingo-
myelin and (lyso)phosphatidylcholine [10,50]), which can act as a
substrate for brown spider phospholipase-D. Choline release assays
demonstrated direct hydrolysis of membrane extracts in a time- andconcentration-dependent manner only with LiRecDT1 treatment
(Fig. 8B), supporting the idea of catalytic-dependent cytotoxicity
and suggesting that products of phospholipases-D degradation induce
formation of bioactive mediators such as C1P or LPA [22,23].
In Fig. 8 (see *), the formation of subproducts induced by hydrolysis
can beobserved inHPTLC images,mainly in the top of those laneswhere
samples were exposed to active phospholipase-D and original lipid
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generatedbyphospholipasesactingonphospholipids inmembranes are
implicated as mediators and second messengers in signal transduction
[51]. For example, autotaxin (ATX) is an exo-enzyme originally
identiﬁed as a tumor cell autocrine and paracrine motility factor.
ATX is a multifunctional phosphodiesterase that primarily acts as a
lysophospholipase D [52,53], converting lysophosphatidylcholine into
LPA. LPAmediates multiple biological functions, including the cytoskel-
etal reorganization and chemotaxis observed in melanoma cells.
Likewise, endothelial cell plasma membranes could be targeted by
phospholipase-D activity, for which the regulation of lipid-derived
second messenger levels intra- and intercellularly is not well under-
stood [54]. Morphological alterations induced by phospholipase-D
activity in RAEC cells could be explained by this hypothesis (Fig. 8B).
Furthermore, thehallmark of brown spider dermonecrotic toxins is both
dermonecrosis andhydrolysis of sphingomyelin,which in tissue context
has been shown to be related to an inﬂammatory overreaction. This
event is triggered by intense an neutrophil migration, which is
dependent on the activation of ﬁbroblast and endothelial cells by
generating lipid mediators (such as C1P, an interconvertible molecule
[22]) that cause a cascade of signaling events as pro-inﬂammatory
cytokines upregulation and leukocytes recruitment [25].
As expected, LiRecDT1 and recombinant toxins obtained from
Loxosceles genus venom glands have the ability to hydrolyze sphin-
gomyelin and lysophospholipids [10,55]. Interestingly, L. intermedia
toxins also hydrolyze phospholipids such as phosphatidylcholine or
PAF (platelet-activating factor), which are non alkyl-phospholipids
(Fig. 8). The resulting lipidmetabolite is phosphatic acid (PA), another
bioactive metabolite related to LPA that has already been reported to
play a role in stimulating several signaling pathways [56]. A juxtacrine
mechanism for neutrophil adhesion on platelets involves platelet-
activating factor and a selectin-dependent activation process, which
are critical in cell–cell interactions in inﬂammatory and thrombotic
responses of endothelial cells [54,57,58]. In the same way, hemo-
static disturbances such as blood coagulation problems have been
reported in with some brown spider bites [59]. In addition, platelet
hyperaggregation was experimentally observed in human blood
platelets exposed to a dermonecrotic toxin from L. recluse [60] and
also thrombus formation and hemorrhage in rabbits tested with
L. gaucho venom [61]. All phospholipids tested as substrates in HPTLC
analysis with LiRecDT1 are important components/targets of plasma
membranes of erythrocytes and platelets, for which phospholipase-D
activity could be triggering several well known biological effects in
brown spider accidents.
5. Conclusion
We present experimental data and literature supporting the direct
involvement of dermonecrotic toxin in the biological effects evoked
by brown spider venom. These data demonstrate phospholipase-D
enzymatic activity on the endothelial cell membrane, suggesting a
non-speciﬁc formation of different lipid mediators from cell mem-
brane phospholipids. Our results bring new insights to the pathologic
processes associatedwith a lipid role in pathways of the inﬂammatory
response and dermonecrosis in Loxoscelism.
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